Triflusal - A review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation

被引：34

作者：

Murdoch, David ^{[1
]}

Plosker, Greg L. ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland 1311, New Zealand

来源：

DRUGS | 2006年 / 66卷 / 05期

关键词：

triflusal; atrial fibrillation; cerebral infarction; myocardial infarction; pharmacodynamics; pharmacoeconomics; pharmacokinetics; stroke; therapeutic use; thromboprophylaxis; tolerability;

D O I：

10.2165/00003495-200666050-00009

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Triflusal (Aflen((R)), Disgren((R)), Tecnosal((R)), Triflux((R))) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk of haemorrhagic complications. In addition, triflusal plus moderate-intensity anticoagulation has demonstrated efficacy when used as thromboprophylaxis in atrial fibrillation. As such, triflusal has a role in the primary prevention of cerebrovascular events in atrial fibrillation, and for the secondary prevention of cerebral and myocardial infarction, primarily as an alternative to aspirin in patients for whom aspirin is unsuitable.

引用

页码：671 / 692

页数：22

共 79 条

[1] Oral administration of the anti-inflammatory substance triflusal results in the downregulation of constitutive transcription factor NF-κB in the postnatal rat brain [J].